About: Romidepsin     Goto   Sponge   Distinct   Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz:8890 associated with source document(s)

AttributesValues
rdf:type
rdfs:label
  • Romidepsin
equivalentClass
Has_Target
Concept_In_Subset
Semantic_Type
  • Amino Acid, Peptide, or Protein
  • Antibiotic
Preferred_Name
  • Romidepsin
NSC_Code
  • 630176
UMLS_CUI
  • C1527027
CAS_Registry
  • 128517-07-7
In_Clinical_Trial_For
  • Cutaneous T-cell lymphoma; Large cell lymphoma; Malignancies involving lungs, esophagus, or pleura; Mesothelioma; Mycosis fungoides; Neoplasms; Non-Hodgkins lymphoma; Non-Small-Cell Lung carcinoma; Sezary syndrome; Small Cell carcinoma
FDA_UNII_Code
  • CX3T89XQBK
Contributing_Source
  • FDA
ALT_DEFINITION
  • A substance being studied in the treatment of cancer. Romidepsin is a type of depsipeptide and histone deacetylase inhibitor.NCI-GLOSS
PDQ_Open_Trial_Search_ID
  • 42600
PDQ_Closed_Trial_Search_ID
  • 42600
Chemical_Formula
  • C24H36N4O6S2
Legacy_Concept_Name
  • Depsipeptide
CHEBI_ID
  • CHEBI:61080
FULL_SYN
  • romidepsinPTNCI-GLOSSCDR0000509038
  • N-[(3S,4E-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, CyclicSNNCI
  • DepsipeptideSYNCI
  • L-Valine, N- (3-hydroxy-7-mercapto-1-oxo-4-heptenyl)valyl- cysteinyl-2, 3-didehydro-2-aminobutanoyl-,.xi.-lactone, cyclic (1.fwdarw.2)-disulfideSNNCI
  • depsipeptidePTNCI-GLOSSCDR0000046707
  • L-Valine, N-(3-Hydroxy-7-Mercapto-1-Oxo-4-Heptenyl)-D-Valyl-D-Cysteinyl-(Z)-2,3 -Didehydro-2-Aminobutanoyl-, xi-Lactone, Cyclic (1-2)-Disulfide, (S-(E))-SNNCI
  • FK228CNNCI
  • FR901228SYNCI-GLOSSCDR0000045521
  • N-[(3S,4E-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, CyclicPTDCP50157
  • IstodaxBRNCI
  • FR901228CNNCI
  • ROMIDEPSINPTFDACX3T89XQBK
  • Antibiotic FR 901228SYNCI
  • RomidepsinPTNCI
DEFINITION
  • A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.NCI
code
  • C1544
http://linked.open...y/mesh/hasConcept
is someValuesFrom of
is sameAs of
Faceted Search & Find service v1.16.121 as of Mar 31 2025


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3240 as of Mar 31 2025, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 13 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software